Milan, Italy

Elsa Melloni


Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Elsa Melloni

Introduction

Elsa Melloni is a prominent inventor based in Milan, Italy. She has made significant contributions to the field of pharmaceuticals, particularly in the treatment of myotonic disorders. Her innovative work has led to the development of a unique compound that addresses critical medical conditions.

Latest Patents

Melloni holds a patent for Safinamide, which is used for treating myotonia. The invention relates to safinamide or a pharmaceutically acceptable salt thereof for use in the treatment of conditions caused by pathological sarcolemma hyperexcitability. This includes any other condition where restoring normal sarcolemma excitability may provide therapeutic benefits. The focus of her patent is primarily on myotonic disorders.

Career Highlights

Elsa Melloni has established herself as a key figure in her field through her innovative research and development efforts. Her work at Zambon S.p.a. has been instrumental in advancing treatments for neuromuscular conditions. She has dedicated her career to improving the quality of life for patients suffering from myotonic disorders.

Collaborations

Melloni has collaborated with notable colleagues, including Jean-François Desaphy and Sabata Pierno. These partnerships have enhanced her research and contributed to the successful development of her patented inventions.

Conclusion

Elsa Melloni's contributions to the field of pharmaceuticals, particularly through her patent for Safinamide, highlight her innovative spirit and dedication to medical advancements. Her work continues to impact the treatment of myotonic disorders, showcasing the importance of research and collaboration in the pursuit of better healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…